Navigation Links
Extended Therapy for Blood Clots

An oral drug given after a standard six-month treatment could help prevent future blood clots in patients, according to new research.//

Venous thromboembolism (VTE) affects approximately 2 million Americans each year. VTE includes deep vein thrombosis (blood clots common in the thigh and back) and pulmonary embolism (blood clots common in the lung). Despite progress in diagnosis and treatment, VTE is still associated with high morbidity and mortality. While previous studies have shown a risk of recurrence after six months, treatment is often stopped after six months because of the risk of bleeding. A new study examines the use of the oral drug ximelagatran or placebo as a treatment after the six-month standard treatment.

The study included 1,233 patients with VTE who had six months of anticoagulant therapy. Half of the patients were then given the drug ximelagatran and the other half was given a placebo for 18 months. Researchers then analyzed how the patients did on the drug compared to those on the placebo.

Researchers report only 12 patients on ximelagatran had a recurrent problem compared with 71 patients on the placebo. They found six patients on the drug died during the 18 months compared with seven patients who died in the placebo group. However, 134 patients on ximelagatran experienced bleeding compared to 111 patients on the placebo. Still, study authors point out that the risk of major hemorrhage was low. Researchers say those patients on ximelagatran had high levels of alanine aminotransferase which is an enzyme present in the liver and heart cells. The levels of this enzyme in patients on the drug were more than three-times the normal level and cause a concern for more research on this treatment, according to study authors.

In conclusion, researchers say the drug ximelagatran is superior to placebo for an extended treatment for VTE. However, they say more research is needed to understand why patients on the tre atment had high levels of a certain enzyme.
'"/>




Related medicine news :

1. Breast Cancer Funding To Be Extended By Another $30 Million: Pharmac
2. Drug Courts In Europe Extended For Three More Years
3. Single Dose Of Extended Release Metformin Found To Be Effective In Type 2 Diabetes
4. Tenure of Mental Health CommissionExtended
5. Pharmaceutical Benefits Scheme Extended for 2 Novel Breast Cancer Drugs
6. Babies with Cleft Conditions, Pierre Robin Sequence May Need Extended Treatment for Poor Feeding Skills
7. Survival of Mice With Human Breast Cancer Extended by Monoclonal Antibodies
8. Cancer Doctors Okays Controversial Prostate Therapy
9. Consensus on "Combination Therapy" for Breast Cancer
10. Gene Therapy shows promise in treating Hemophilia
11. "Make AIDS Therapy affordable" - Physicians demand
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:6/26/2016)... North Carolina (PRWEB) , ... June 26, 2016 , ... ... release of a new product that was developed to enhance the health of felines. ... for centuries. , The two main herbs in the PawPaws Cat Kidney Support ...
(Date:6/25/2016)... ... , ... The temporary closing of Bruton Memorial Library on June 21 due to a possible ... often overlooked aspect of head lice: the parasite’s ability to live away from a human ... but a necessary one in the event that lice have simply gotten out of control. ...
(Date:6/25/2016)... ... June 25, 2016 , ... On Friday, June 10, ... Bronze Wellness at Work award to iHire in recognition of their exemplary accomplishments in ... the 7th annual Maryland Workplace Health & Wellness Symposium at the BWI Marriott in ...
(Date:6/24/2016)... ... June 24, 2016 , ... Marcy was in a crisis. Her son James, eight, ... at his family verbally and physically. , “When something upset him, he couldn’t control his ... it. He would throw rocks at my other children and say he was going to ...
(Date:6/24/2016)... ... ... BioMedics, Inc, makers of Topricin and MyPainAway Pain Relief Products, join The ‘Business for a ... an hour by 2020 and then adjusting it yearly to increase at the same rate ... assure the wage floor does not erode again, and make future increases more predictable. , ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... , June 23, 2016 Research ... MEMS Devices Medical Market Analysis 2016 - Forecast to 2022" ... The report contains up to date financial data ... analysis. Assessment of major trends with potential impact on the ... analysis of market segmentation which comprises of sub markets, regional ...
(Date:6/23/2016)... -- Bracket , a leading clinical trial technology and ... platform, Bracket eCOA (SM) 6.0, at the 52 nd ... 2016 in Philadelphia , Pennsylvania.  A demonstration ... of its kind to fully integrate with RTSM, will be ... is a flexible platform for electronic clinical outcomes assessments that ...
(Date:6/23/2016)... 2016  Astellas today announced the establishment of Astellas Farma Colombia (AFC), a new affiliate with operations headquartered in ... America . ... ... ... ...
Breaking Medicine Technology: